{"nctId":"NCT02114931","briefTitle":"Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis","startDateStruct":{"date":"2014-04"},"conditions":["Arthritis, Rheumatoid"],"count":467,"armGroups":[{"label":"ABP 501","type":"EXPERIMENTAL","interventionNames":["Biological: ABP 501"]}],"interventions":[{"name":"ABP 501","otherNames":["AMJEVITA™","Adalimumab-atto"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject was randomized into protocol 20120262 (NCT01970475) and completed the week 26 visit\n\nExclusion Criteria:\n\n* Subject experienced a serious adverse event (SAE) or an adverse event (AE) in the 20120262 study that could cause extension treatment to be detrimental\n* Subject completed study 20120262 but cannot be dosed within 4 weeks of the week 26 visit of study 20120262\n* Current infection requiring the use of oral or intravenous antibiotics\n\nOther Inclusion/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"81 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"Adverse events (AEs) were graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 according to the following scale:\n\n1 = mild; 2 = moderate; 3 = severe; 4 = life-threatening; 5 = fatal. A treatment-related AE is defined as an event where the answer to the question \"is there a reasonable possibility that the event may have been caused by the Investigational Medicinal Product\" was yes.\n\nA serious adverse event is defined as an AE that meets at least 1 of the following serious criteria:\n\n* fatal\n* life threatening (places the subject at immediate risk of death)\n* requires inpatient hospitalization or prolongation of existing hospitalization\n* results in persistent or significant disability/incapacity\n* congenital anomaly/birth defect\n* other medically important serious event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"154","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Grade ≥ 3 Hematology and Chemistry Laboratory Results","description":"Laboratory results were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 according to the following scale:\n\n1 = mild; 2 = moderate; 3 = severe; 4 = life-threatening; 5 = fatal.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Developed Antibodies to ABP 501","description":"Two validated assays were used to detect the presence of anti-drug antibodies. All samples were first tested in an electrochemiluminescence (ECL)-based bridging immunoassay to detect anti-drug antibodies against ABP 501 (Binding Antibody Assay). Samples confirmed to be positive for binding antibodies were subsequently tested in a non-cell based bioassay to determine neutralizing activity against ABP 501. If a sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the sample was defined as positive for neutralizing antibodies.\n\nPreexisting antibody positive indicates participants with a positive result at baseline of the extension study. Developing antibody positive indicates participants with a negative or no result at baseline of the extension study who were positive at any time point post-baseline during the extension study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":null},{"groupId":"OG001","value":"34.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","spread":null},{"groupId":"OG001","value":"14.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":null},{"groupId":"OG001","value":"5.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an American College of Rheumatology (ACR) 20 Response","description":"A participant was a responder if the following 3 criteria for improvement from Baseline of the parent study were met:\n\n* ≥ 20% improvement in tender joint count;\n* ≥ 20% improvement in swollen joint count; and\n* ≥ 20% improvement in at least 3 of the 5 following parameters:\n\n  * Patient's assessment of pain (measured on a 100 mm visual analog scale \\[VAS\\]);\n  * Patient's global assessment of disease activity (measured on a likert scale from 0 to 10);\n  * Physician's global assessment of disease activity (measured on a likert scale from 0 to 10);\n  * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \\[HAQ-DI\\]);\n  * C-Reactive Protein level.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","spread":null},{"groupId":"OG001","value":"73.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":null},{"groupId":"OG001","value":"77.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.0","spread":null},{"groupId":"OG001","value":"74.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":null},{"groupId":"OG001","value":"78.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":null},{"groupId":"OG001","value":"78.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Parent Study Baseline in Disease Activity Score 28-C-reactive Protein (DAS28-CRP)","description":"The DAS28-CRP is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables:\n\n* The number of swollen and tender joints assessed using the 28-joint count;\n* C-reactive protein (CRP) level\n* Patient's global assessment of disease activity assessed on a score from 0 to 100 transformed from the result measured on a horizontal scale from 0 (no RA activity at all) to 10 (worst RA activity imaginable).\n\nThe DAS28-CRP score ranges from approximately zero to ten. Higher DAS28-CRP scores indicate higher disease activity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.26","spread":"1.255"},{"groupId":"OG001","value":"-2.25","spread":"1.289"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.40","spread":"1.322"},{"groupId":"OG001","value":"-2.32","spread":"1.257"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.49","spread":"1.272"},{"groupId":"OG001","value":"-2.33","spread":"1.316"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.59","spread":"1.433"},{"groupId":"OG001","value":"-2.51","spread":"1.414"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.70","spread":"1.389"},{"groupId":"OG001","value":"-2.51","spread":"1.445"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":229},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Bronchitis","Rheumatoid arthritis","Hypertension"]}}}